In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xytis Pharmaceuticals Inc.

Latest From Xytis Pharmaceuticals Inc.

Treating Traumatic Brain Injury

Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?


Recent Financings of Private Companies (02/2006)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Xytis Pharmaceuticals Ltd.

Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.

BioPharmaceutical Research and Development Strategies

Building a Better Drug for Schizophrenia

Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals